We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+29.15%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$899M
AUM Growth
+$115M
Cap. Flow
+$36.7M
Cap. Flow %
4.08%
Top 10 Hldgs %
99.85%
Holding
13
New
1
Increased
7
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$64.6M
2
ABBV icon
AbbVie
ABBV
+$27.2M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$18M
4
ALKS icon
Alkermes
ALKS
+$10.3M
5
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$5.27M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$82.8M
2
MRSN
Mersana Therapeutics
MRSN
+$16.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$30B
$172M 19.14%
643,000
– –
ALKS icon
2
Alkermes
ALKS
$8.22B
$152M 16.89%
7,825,000
+632,000
+9% +$10.3M
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$696M
$145M 16.12%
14,040,000
+515,000
+4% +$5.27M
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$15.9B
$102M 11.39%
928,100
+163,100
+21% +$18M
INVA icon
5
Innoviva
INVA
$1.55B
$89.7M 9.98%
6,414,000
+172,000
+3% +$2.34M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$83.5M 9.28%
743,500
+608,500
+451% +$64.6M
MRSN
7
DELISTED
Mersana Therapeutics
MRSN
$60.1M 6.69%
102,800
-47,200
-31% -$16.1M
ICPT
8
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$57.5M 6.4%
1,201,000
+46,000
+4% +$3.55M
ABBV icon
9
AbbVie
ABBV
$443B
$30.4M 3.39%
310,150
+309,150
+30,915% +$27.2M
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.28B
$5.12M 0.57%
+1,075,000
New +$4.29M
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
$1.26M 0.14%
185,185
– –
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$114K 0.01%
1,000
– –
AGN
13
DELISTED
Allergan plc
AGN
– –
-467,500
Closed -$82.8M

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Sarissa Capital Management held 13 positions worth $899M, up 15% from $784M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management deployed $36.7M of net new capital in Q2 2020, opening 1 new position and adding to 7 existing holdings. Its largest new stake was BioCryst Pharmaceuticals: 1,075,000 shares worth $5.12M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Mersana Therapeutics, an estimated $16.1M trimmed.

  • Sarissa Capital Management's largest Q2 2020 buy was BioCryst Pharmaceuticals: 1,075,000 shares worth $5.12M.
  • Sarissa Capital Management added most to Alexion Pharmaceuticals in Q2 2020, an estimated $64.6M increase.
  • Sarissa Capital Management's biggest Q2 2020 reduction was Mersana Therapeutics, cutting an estimated $16.1M.
  • Sarissa Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $82.8M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $899M portfolio in Q2 2020.
  • Sarissa Capital Management opened 1 new position and closed 1 in Q2 2020.
  • Sarissa Capital Management's portfolio value rose 15% quarter-over-quarter to $899M.

Based on Sarissa Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.